ACA
LGND icon

American Capital Advisory’s Ligand Pharmaceuticals LGND Stock Holding History

American Capital Advisory’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$757 – 1176
2025
Q4 		$757 Buy
+4
New +$769 ﹤0.01% 659

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

American Capital Advisory's LGND Position: Q1 2026 in Review

American Capital Advisory sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 4 shares — an estimated $757 sold.

American Capital Advisory first reported a position in LGND in Q4 2025 and held it in 1 quarter. The position peaked at $757 in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • American Capital Advisory reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • American Capital Advisory sold 4 Ligand Pharmaceuticals shares in Q1 2026, an estimated $757.
  • American Capital Advisory first reported a position in Ligand Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • American Capital Advisory's Ligand Pharmaceuticals position peaked at $757 in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on American Capital Advisory's 13F filing for Q1 2026, filed 29 Apr 2026.